Atossa Therapeutics, Inc.
NASDAQ:ATOS
1.52 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.002 | 0.526 | 0.633 | 0.482 | 0.002 | 0 |
| Cost of Revenue
| 0.023 | 0.008 | 0.023 | 0.047 | 0.053 | 0.044 | 0.129 | 0.303 | 0.132 | 0.341 | 0.495 | 0.066 | 0.097 | 0 |
| Gross Profit
| -0.023 | -0.008 | -0.023 | -0.047 | -0.053 | -0.044 | -0.129 | -0.303 | -0.131 | 0.185 | 0.137 | 0.416 | -0.096 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -74.319 | 0.352 | 0.217 | 0.864 | -63.793 | 0 |
| Reseach & Development Expenses
| 17.334 | 15.083 | 9.21 | 6.608 | 6.645 | 4.21 | 2.328 | 0.77 | 2.36 | 2.577 | 1.105 | 0.002 | 0 | 0.12 |
| General & Administrative Expenses
| 14.043 | 12.608 | 11.311 | 7.999 | 10.62 | 7.224 | 4.859 | 6.479 | 8.847 | 8.626 | 8.559 | 5.018 | 3.173 | 0.882 |
| Selling & Marketing Expenses
| 14.006 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.421 | 1.272 | 1.258 | 0.467 | 0.161 | 0.012 |
| SG&A
| 14.02 | 12.608 | 11.311 | 7.999 | 10.62 | 7.224 | 4.859 | 6.479 | 10.268 | 9.898 | 9.817 | 5.485 | 3.334 | 0.894 |
| Other Expenses
| 0 | -0.146 | -0.085 | 0.051 | 0.026 | 0.029 | 0 | 0.719 | 0 | 2.012 | 0 | 0 | 0 | 0.064 |
| Operating Expenses
| 31.354 | 27.691 | 20.521 | 14.607 | 17.265 | 11.434 | 7.187 | 7.25 | 12.628 | 12.475 | 10.922 | 5.485 | 3.334 | 1.078 |
| Operating Income
| -31.377 | -27.691 | -20.521 | -14.607 | -17.265 | -11.434 | -7.649 | -7.969 | -12.759 | -14.642 | -10.785 | -5.069 | -3.429 | -1.078 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7,257.462 | -27.84 | -17.049 | -10.52 | -2,286.127 | 0 |
| Total Other Income Expenses Net
| 1.283 | 0.731 | -0.085 | -3.221 | 0.026 | 0.029 | -0.935 | 0.881 | 0 | -2.353 | -0 | -0.011 | -0.013 | -0.009 |
| Income Before Tax
| -30.094 | -26.96 | -20.606 | -17.828 | -17.24 | -11.405 | -8.123 | -6.369 | -12.758 | -14.658 | -10.785 | -5.08 | -3.442 | -1.087 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7,257.217 | -27.869 | -17.049 | -10.543 | -2,294.846 | 0 |
| Income Tax Expense
| 0 | -0.731 | -0.214 | 3.271 | -0.119 | -0.029 | 0.742 | -1.761 | 3.001 | 2.353 | 0 | 0.011 | 0.013 | 0 |
| Net Income
| -30.094 | -26.229 | -20.606 | -21.099 | -17.24 | -11.405 | -8.123 | -6.369 | -15.76 | -14.658 | -10.785 | -5.08 | -3.442 | -1.087 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8,964.916 | -27.869 | -17.049 | -10.543 | -2,294.846 | 0 |
| EPS
| -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.96 |
| EPS Diluted
| -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.58 |
| EBITDA
| -31.354 | -27.691 | -20.498 | -11.29 | -17.213 | -11.39 | -6.252 | -7.827 | -12.486 | -12.29 | -10.311 | -4.937 | -3.409 | -1.078 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7,102.629 | -23.366 | -16.301 | -10.247 | -2,272.436 | 0 |